Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
An erratum to this article was published (Rheumatology (Oxford), 1 Nov 2024 ↗)
Authors' conclusion
The efficacy and safety of TOF, BAR, PEF and UPA were not significantly different for the treatment of patients with rheumatoid arthritis.
Study context
- Population
- Patients with RA treated with JAKi, ANSWER cohort database
- Participants
- 622 patients
- Exposure
- Tofacitinib vs baricitinib vs peficitinib vs upadacitinib
- Outcome
- CDAI, CRP and modified Health Assessment Questionnaire (mHAQ) after drug initiation and CDAI remission or low disease activity (LDA) rates
- Follow-up
- 6 months
Methodological detailsmulticentre, propensity score-based inverse probability of treatment weighting (IPTW)
- Multicentre
- Propensity score-based IPTW
Main finding
As reported in the abstract
Mean CDAI, CDAI remission rate and CDAI-LDA rate
- Mean Clinical Disease Activity Index (CDAI), CDAI remission rate and CDAI-LDA rate not significantly different among treatment groups
Observational data: associations, not effects.
Further findings
Retention and discontinuation rates · until 6 months
- Not significantly different among the four JAKi groups
Predictive factors for resistance to CDAI-LDA achievement
- Baseline CDAI (TOFA): OR
- 1.09, P < 0.001
- Baseline CDAI (BARI): OR
- 1.07, P < 0.001
- Baseline C-reactive protein (CRP) (TOFA): OR
- 1.32, P = 0.049
- Baseline GC dose (BARI): OR, 95% CI
- 1.18, 1.01-1.38, P = 0.035
- Number of previous b/tsDMARDs (BARI): OR
- 1.36, P = 0.004
Original publication
Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Rheumatology (Oxford). Published 1 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →